Elgemtumab
- Generic Name
- Elgemtumab
- Drug Type
- Biotech
- CAS Number
- 1512559-37-3
- Unique Ingredient Identifier
- 5F1CN52GFM
- Background
Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT02167854
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Commack, Commack, New York, United States
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01822613
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Manchester, United Kingdom
๐บ๐ธUniversity of Chicago Medical Center Dept of Onc, Chicago, Illinois, United States
๐บ๐ธKarmanos Cancer Institute Dept of Onc, Detroit, Michigan, United States
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
- Conditions
- Advanced HER2-positive Breast Cancer or Gastric Cancer
- Interventions
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT01602406
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Oxford, United Kingdom
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
- Conditions
- HER2 + Gastric CancerEsophageal Squamous Cell CarcinomaHER2 + Breast CancerHER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01598077
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Taipei, Taiwan
๐บ๐ธUniversity of Chicago Medical Center University of Chicago (16), Chicago, Illinois, United States
๐บ๐ธMassachusetts General Hospital SC-5, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.